Split high‐dose oral levothyroxine treatment as a successful therapy option in myxedema coma

High‐dose intravenous thyroxine (T4) is the preferable treatment for myxedema coma. We describe the clinical course of a 69‐year‐old man who presented with myxedema coma and received oral levothyroxine (LT4) therapy (1 mg) in a split dose. This suggests split high‐dose oral LT4 as a therapeutic opti...

Descripción completa

Detalles Bibliográficos
Autores principales: Charoensri, Suranut, Sriphrapradang, Chutintorn, Nimitphong, Hataikarn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628197/
https://www.ncbi.nlm.nih.gov/pubmed/29026577
http://dx.doi.org/10.1002/ccr3.1131
_version_ 1783268833153253376
author Charoensri, Suranut
Sriphrapradang, Chutintorn
Nimitphong, Hataikarn
author_facet Charoensri, Suranut
Sriphrapradang, Chutintorn
Nimitphong, Hataikarn
author_sort Charoensri, Suranut
collection PubMed
description High‐dose intravenous thyroxine (T4) is the preferable treatment for myxedema coma. We describe the clinical course of a 69‐year‐old man who presented with myxedema coma and received oral levothyroxine (LT4) therapy (1 mg) in a split dose. This suggests split high‐dose oral LT4 as a therapeutic option in myxedema coma.
format Online
Article
Text
id pubmed-5628197
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56281972017-10-12 Split high‐dose oral levothyroxine treatment as a successful therapy option in myxedema coma Charoensri, Suranut Sriphrapradang, Chutintorn Nimitphong, Hataikarn Clin Case Rep Case Reports High‐dose intravenous thyroxine (T4) is the preferable treatment for myxedema coma. We describe the clinical course of a 69‐year‐old man who presented with myxedema coma and received oral levothyroxine (LT4) therapy (1 mg) in a split dose. This suggests split high‐dose oral LT4 as a therapeutic option in myxedema coma. John Wiley and Sons Inc. 2017-09-08 /pmc/articles/PMC5628197/ /pubmed/29026577 http://dx.doi.org/10.1002/ccr3.1131 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Charoensri, Suranut
Sriphrapradang, Chutintorn
Nimitphong, Hataikarn
Split high‐dose oral levothyroxine treatment as a successful therapy option in myxedema coma
title Split high‐dose oral levothyroxine treatment as a successful therapy option in myxedema coma
title_full Split high‐dose oral levothyroxine treatment as a successful therapy option in myxedema coma
title_fullStr Split high‐dose oral levothyroxine treatment as a successful therapy option in myxedema coma
title_full_unstemmed Split high‐dose oral levothyroxine treatment as a successful therapy option in myxedema coma
title_short Split high‐dose oral levothyroxine treatment as a successful therapy option in myxedema coma
title_sort split high‐dose oral levothyroxine treatment as a successful therapy option in myxedema coma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628197/
https://www.ncbi.nlm.nih.gov/pubmed/29026577
http://dx.doi.org/10.1002/ccr3.1131
work_keys_str_mv AT charoensrisuranut splithighdoseorallevothyroxinetreatmentasasuccessfultherapyoptioninmyxedemacoma
AT sriphrapradangchutintorn splithighdoseorallevothyroxinetreatmentasasuccessfultherapyoptioninmyxedemacoma
AT nimitphonghataikarn splithighdoseorallevothyroxinetreatmentasasuccessfultherapyoptioninmyxedemacoma

Ejemplares similares